Novartis to open ‘new chapter’ of CVD treatment with NHS collaboration

Novartis aims to work alongside NHS England to tackle the burden of cardiovascular disease (CVD) in the UK.

Announcing its intentions, Novartis said the current proposal is to create a pioneering collaboration that brings together three projects that aim to tackle the healthcare challenge of CVD, whilst also providing increased opportunities for UK life science sector development.

The current Memorandums of Understanding (MOUs), which form the basis of the collaboration, were negotiated and signed by The Medicines Company prior to its acquisition by Novartis.

The first proposal, upon regulatory approval and the National Institute for Health and Care Excellence (NICE) assessment, would be to provide inclisiran to secondary prevention ASCVD patients through a population-level agreement.

Inclisiran is currently in Phase III development for secondary prevention patients with expected European Medicines Agency (EMA) regulatory filing in Q1 2020.

Providing inclisiran to this high-risk population could make a significant contribution towards meeting the NHS long-term commitment to preventing 150,000 cardiovascular deaths over 10 years.

The second proposal is to explore a large-scale clinical trial to evaluate the use of inclisiran to patients at very high risk of having their first cardiac event (primary prevention).

The final proposal includes the creation of an industry and academic consortium to look at manufacturing synergies that could improve the efficiency and scale at which the UK can manufacture oligonucleotide medicines – such as inclisiran.

Novartis has a unique opportunity with inclisiran to open up a new chapter in the treatment of cardiovascular disease, the world’s leading cause of mortality and disability,” said Vas Narasimhan, CEO of Novartis.

“We’re confident that innovative approaches like this will enable us to accelerate access timelines, deliver on our broader commitment to generating leading scientific evidence, and ensure continuous improvement in manufacturing efficiency and optimisation.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...

Atomwise announces partnerships to tackle COVID-19

Atomwise, a San Fran company using AI for small molecule drug discovery, has announced it has fifteen research collaborations underway with leading global universities...

GSK secures additional biopharma capacity via Samsung Biologics partnership

GlaxoSmithKline (GSK) has secured additional manufacturing capacity for its biopharmaceutical portfolio by partnering with South Korea’s Samsung Biologics. As per the agreement, Samsung Biologics will...

Related news

Chimeron Bio & NCBID to develop COVID-19 vaccine

RNA therapeutics company, Chimeron Bio, and George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID), will together develop a COVID-19 vaccine. The vaccine...

AbCellera raises $105m to advance antibody drug discovery platform

AbCellera has closed a $105 million Series B financing to further advance its antibody drug discovery platform. The financing was led by OrbiMed and current...

Novavax expands large-scale manufacturing capacity

Novavax, a late-stage biotech developing next-gen vaccines for serious infectious diseases, has expanded its large-scale manufacturing capacity with the $167 million acquisition of Praha...

Gilead & Arcus partner to develop next-gen cancer immunotherapies

Gilead Sciences and Arcus Biosciences, an oncology-focused biopharma working to create best-in-class cancer therapeutics, have entered into a ten-year partnership to co-develop and co-commercialise...